CervoMed

CervoMed Gross Margin

The Gross Margin of CervoMed (CRVO) as of Oct 25, 2026 is -93.04 %. In the previous year, Gross Margin was -18.11 % — a change of 413.72% (lower).

Gross Margin

-93.04 %

YoY

413.72%

Last updated:

Gross Margin of CervoMed is 2024 -93.04 % . Gross Margin of CervoMed was 2023 -18.11 % . It decreases by 413.72% lower compared to the previous year.

For CervoMed, the gross margin of -93.0% is up versus -304.7% a few years ago.

The CervoMed Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2007
0.57 USD
Jan 1, 2008
0.39 USD
Jan 1, 2010
-4.23 USD
Jan 1, 2011
-3.05 USD
Jan 1, 2012
0.37 USD
Jan 1, 2013
-8.43 USD
Jan 1, 2023
-18.11 USD
Jan 1, 2024
-93.04 USD
The CervoMed Gross Margin history
YEARGross MarginYoY
-93.04 %+413.72%
-18.11 %+114.89%
-8.43 %-2,375.20%
0.37 %-112.16%
-3.05 %-27.98%
-4.23 %-1,196.07%
0.39 %-31.76%
0.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CervoMed Stock analysis

What does CervoMed do? CervoMed Inc. generates revenue through the development and clinical advancement of its lead product candidate, neflamapimod, a small molecule brain penetrant targeting p38MAP kinase alpha. The company focuses on clinical-stage therapeutics for degenerative brain diseases, with neflamapimod in Phase IIb trials for dementia with Lewy Bodies (DLB), early Alzheimer’s disease, and stroke recovery. Its wholly owned subsidiary, EIP Pharma Inc., supports these efforts. CervoMed targets medical institutions and research organizations involved in neurodegenerative disease treatment, seeking partnerships for clinical trials and future commercialization. The company's primary product, neflamapimod, is designed to address synaptic dysfunction in neurodegenerative disorders, positioning it for potential disease-modifying treatments in DLB and related conditions. CervoMed's clinical development strategy centers on advancing this candidate through Phase IIb studies, aiming to secure regulatory approvals and eventual market entry. The firm's operations are structured around its subsidiary, EIP Pharma Inc., which handles specific therapeutic development tasks. CervoMed Inc. operates as a clinical-stage biotechnology company, relying on the progress of its lead candidate to attract investment and strategic collaborations. Its focus on CNS-focused therapeutics for degenerative brain diseases aligns with unmet medical needs in neurology, targeting healthcare providers and pharmaceutical partners interested in innovative treatments for conditions like DLB and Alzheimer’s disease. CervoMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CervoMed stock

Gross Margin of CervoMed is -93.04 % in 2024.

Gross Margin of CervoMed changed from -18.11 % to -93.04 %, representing a 413.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin CervoMed since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's CervoMed with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — CervoMed

All Key Metrics — CervoMed